Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is CSPC Pharmaceutical Group Limited CHPTY. This firm, which is in the Medical-Drugs industry, saw EPS growth of 31.4% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 25.6%. Furthermore, the long-term growth rate is currently an impressive 23%, suggesting pretty good prospects for the long haul.
CSPC PHARMA-ADR Price and Consensus
CSPC PHARMA-ADR Price and Consensus | CSPC PHARMA-ADR Quote
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 3.2%. Thanks to this rise in earnings estimates, CHPTY has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider CHPTY. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for CHPTY as well.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CSPC PHARMA-ADR (CHPTY): Free Stock Analysis Report
To read this article on Zacks.com click here.